AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10980586 — intervention group
Group type: EXPERIMENTAL
Intervention: High intake of saturated fats
Number of subjects: 815
Study 10980586 — intervention group
Group type: COMPARATOR
Intervention: Hypertensive subjects
Number of subjects: 815
Study 10980586 — intervention group
Group type: COMPARATOR
Intervention: Non-hypertensive subjects
Number of subjects: 815
Study 8830940 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-h preoxygenation with exercise
Number of subjects: 74
Study 8830940 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-min preoxygenation with exercise
Number of subjects: 74
Study 8830940 — intervention group
Group type: COMPARATOR
Intervention: 1-h resting preoxygenation
Number of subjects: 74
Study 1521973 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive intervention group
Number of subjects: 1600
Study 1521973 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 1600
Study 1521973 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsingle family residence
Number of subjects: 1600
Study 1521973 — intervention group
Group type: EXPERIMENTAL
Intervention: No alcohol use
Number of subjects: 1600
Study 1521973 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 1600
Study 1521973 — intervention group
Group type: EXPERIMENTAL
Intervention: Group assignment
Number of subjects: 1600
Study 2866837 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam (30 mg)
Number of subjects: 0
Study 2866837 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.5 mg)
Number of subjects: 0
Study 2866837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29998770 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral planning intervention (six sessions)
Number of subjects: 58
Study 29998770 — intervention group
Group type: COMPARATOR
Intervention: Waitlist condition
Number of subjects: 58
Study 28514320 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 minutes of forced air warming plus intravenous fluid warming
Number of subjects: 50
Study 28514320 — intervention group
Group type: COMPARATOR
Intervention: No active preoperative warming plus intravenous fluid warming
Number of subjects: 50
Study 27870739 — intervention group
Group type: EXPERIMENTAL
Intervention: Angle Labor Pain Questionnaire (A‐LPQ) administered before epidural insertion (Test 1)
Number of subjects: 51
Study 27870739 — intervention group
Group type: EXPERIMENTAL
Intervention: Angle Labor Pain Questionnaire (A‐LPQ) administered 20 to 30 minutes after test dose (Test 2)
Number of subjects: 51
Study 27870739 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐LPQ summary scores
Number of subjects: 51
Study 27870739 — intervention group
Group type: EXPERIMENTAL
Intervention: Numeric Rating Scale for overall pain intensity
Number of subjects: 51
Study 27870739 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal Rating Scale (VRS) scores
Number of subjects: 51
Study 27870739 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Mastery Scale for coping
Number of subjects: 51
Study 23671205 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased total cholesterol/HDL
Number of subjects: 413
Study 23671205 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased LDL/HDL
Number of subjects: 413
Study 23671205 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cholesterol
Number of subjects: 413
Study 23671205 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL cholesterol
Number of subjects: 413
Study 22658477 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.15 mg/kg
Number of subjects: 60
Study 22658477 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (Control)
Number of subjects: 60
Study 20533147 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcurrent therapy (M)
Number of subjects: 78
Study 20533147 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (S)
Number of subjects: 78
Study 18544524 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol
Number of subjects: 60
Study 18544524 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 60
Study 18544524 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 60
Study 15286546 — intervention group
Group type: EXPERIMENTAL
Intervention: Sivelestat (0.16 mg.kg(‐1)hr(‐1))
Number of subjects: 492
Study 15286546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 492
Study 15286546 — intervention group
Group type: EXPERIMENTAL
Intervention: Sivelestat
Number of subjects: 492
Study 11195983 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg alprazolam
Number of subjects: 67
Study 11195983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 11195983 — intervention group
Group type: COMPARATOR
Intervention: Nonfearful women
Number of subjects: 67
Study 9263388 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenously and orally administered trimethoprim
Number of subjects: 0
Study 8112375 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (20 mg per day)
Number of subjects: 18
Study 8112375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3771809 — intervention group
Group type: EXPERIMENTAL
Intervention: l-norepinephrine infusion (4 to 16 micrograms/min)
Number of subjects: 6
Study 30334693 — intervention group
Group type: EXPERIMENTAL
Intervention: VX-659-tezacaftor-ivacaftor
Number of subjects: 0
Study 30334693 — intervention group
Group type: COMPARATOR
Intervention: Tezacaftor-ivacaftor
Number of subjects: 0
Study 27206497 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT) preoperative intervention
Number of subjects: 90
Study 27206497 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CBT intervention)
Number of subjects: 90
Study 24990275 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark chocolate (40 g, >85% cocoa)
Number of subjects: 20
Study 24990275 — intervention group
Group type: COMPARATOR
Intervention: Milk chocolate (40 g, ≤35% cocoa)
Number of subjects: 20
Study 21131310 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training and cell phone follow-up
Number of subjects: 70
Study 21131310 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training only
Number of subjects: 70
Study 21131310 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study 21131310 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training plus cell phone
Number of subjects: 70
Study 20512062 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated interferon‐alpha2a
Number of subjects: 114
Study 20512062 — intervention group
Group type: COMPARATOR
Intervention: placebo or ribavirin
Number of subjects: 114
Study 18242883 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengths-based case management (SBCM), n=222
Number of subjects: 678
Study 18242883 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI), n=226
Number of subjects: 678
Study 18242883 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC), n=230
Number of subjects: 678
Study 16020940 — intervention group
Group type: EXPERIMENTAL
Intervention: Virgin argan oil (VAO) 25 g/day for 3 weeks
Number of subjects: 60
Study 16020940 — intervention group
Group type: COMPARATOR
Intervention: Extra virgin olive oil (EVO) 25 g/day for 3 weeks
Number of subjects: 60
Study 14623832 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice, elevation, Tubigrip, and exercise
Number of subjects: 0
Study 14623832 — intervention group
Group type: EXPERIMENTAL
Intervention: Crutches, early weight bearing, and non-steroidal anti-inflammatory drugs
Number of subjects: 0
Study 14623832 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest
Number of subjects: 0
Study 14623832 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 0
Study 14623832 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow up
Number of subjects: 0
Study 10390254 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 118
Study 10390254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 8874336 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychologic distress screening program with monthly telephone screening and additional psychosocial intervention for high distress patients
Number of subjects: 282
Study 8874336 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving brief psychosocial intervention from a social worker at initial treatment
Number of subjects: 282
Study 8874336 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group receiving brief psychosocial intervention from a social worker at initial treatment
Number of subjects: 282
Study 8874336 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal psychosocial intervention at initial treatment
Number of subjects: 282
Study 1997689 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (4 courses at 28-day intervals of 100 mg/M2 cisplatin, 60 mg/M2 doxorubicin, and 600 mg/M2 cyclophosphamide)
Number of subjects: 91
Study 1997689 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 91
Study 6394405 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionization with diclofenac sodium (150 mg)
Number of subjects: 24
Study 6394405 — intervention group
Group type: COMPARATOR
Intervention: Placebo (ionization with saline solution)
Number of subjects: 24
Study 31971597 — intervention group
Group type: EXPERIMENTAL
Intervention: Presatovir
Number of subjects: 28
Study 31971597 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 28
Study 30867067 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic supplementation (10 g/day for healthy subjects, 20 g/day for frail subjects)
Number of subjects: 0
Study 30867067 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 g/day maltodextrin)
Number of subjects: 0
Study 30867067 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber/low-fat diet
Number of subjects: 0
Study 30867067 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fiber/high-fat diet
Number of subjects: 0
Study 30560096 — intervention group
Group type: EXPERIMENTAL
Intervention: Open supraglottic laryngectomy
Number of subjects: 41
Study 30560096 — intervention group
Group type: COMPARATOR
Intervention: Laser supraglottic laryngectomy (CO2 laser)
Number of subjects: 41
Study 26655559 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel plus gemcitabine (nab-P/Gem)
Number of subjects: 421
Study 26655559 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine (Gem)
Number of subjects: 421
Study 24970377 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle changes including a polyphenol-rich modified Mediterranean diet and physical exercise (30 min/day)
Number of subjects: 108
Study 24970377 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (100 ml for women, 200 ml for men)
Number of subjects: 108
Study 24970377 — intervention group
Group type: COMPARATOR
Intervention: Control group (avoiding alcohol)
Number of subjects: 108
Study 22516873 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ART (arm 1)
Number of subjects: 0
Study 22516873 — intervention group
Group type: COMPARATOR
Intervention: Sequential ART interruptions (arm 2)
Number of subjects: 0
Study 19681410 — intervention group
Group type: EXPERIMENTAL
Intervention: Subarachnoid morphine, bupivacaine and fentanyl
Number of subjects: 60
Study 19681410 — intervention group
Group type: EXPERIMENTAL
Intervention: Subarachnoid morphine and bupivacaine
Number of subjects: 60
Study 19681410 — intervention group
Group type: COMPARATOR
Intervention: Subarachnoid morphine only
Number of subjects: 60
Study 17235584 — intervention group
Group type: EXPERIMENTAL
Intervention: Left colectomy combined with radical lymphadenectomy
Number of subjects: 124
Study 17235584 — intervention group
Group type: COMPARATOR
Intervention: Conventional left colectomy
Number of subjects: 124
Study 15129601 — intervention group
Group type: EXPERIMENTAL
Intervention: NTI splint
Number of subjects: 30
Study 15129601 — intervention group
Group type: COMPARATOR
Intervention: Stabilisation splint
Number of subjects: 30
Study 11283049 — intervention group
Group type: EXPERIMENTAL
Intervention: cagA-lacking strain
Number of subjects: 156
Study 11283049 — intervention group
Group type: EXPERIMENTAL
Intervention: tobacco smoking
Number of subjects: 156
Study 11283049 — intervention group
Group type: EXPERIMENTAL
Intervention: double dose of proton pump inhibitor
Number of subjects: 156
Study 9133967 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 15 mg weekly
Number of subjects: 174
Study 9133967 — intervention group
Group type: COMPARATOR
Intervention: Gold sodium thiomalate (GSTM) 50 mg weekly
Number of subjects: 174
Study 12369757 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride 1 mg
Number of subjects: 12
Study 12369757 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride 2 mg
Number of subjects: 12
Study 12369757 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride 4 mg
Number of subjects: 12
Study 12369757 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride 8 mg
Number of subjects: 12
Study 12369757 — intervention group
Group type: COMPARATOR
Intervention: Standardised carbohydrate diet
Number of subjects: 12
Study 12341738 — intervention group
Group type: EXPERIMENTAL
Intervention: TCu 200 IUD with string
Number of subjects: 84
Study 12341738 — intervention group
Group type: COMPARATOR
Intervention: TCu 200 IUD without string
Number of subjects: 84
Study 12341738 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 84
Study 31986111 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional Rehabilitation after Botulinum Toxin-A
Number of subjects: 0
Study 31986111 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional rehabilitation)
Number of subjects: 0
Study 30407958 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental protocol with resuscitation-automating devices and goal-directed algorithmic protocol
Number of subjects: 20
Study 30407958 — intervention group
Group type: COMPARATOR
Intervention: Standard protocols and equipment
Number of subjects: 20
Study 27288384 — intervention group
Group type: EXPERIMENTAL
Intervention: Online intervention (REFRESH)
Number of subjects: 80
Study 27288384 — intervention group
Group type: COMPARATOR
Intervention: Leaflet comparator
Number of subjects: 80
Study 24876490 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial stimulation intervention (weekly visits from community health workers for 2 years)
Number of subjects: 105
Study 24876490 — intervention group
Group type: COMPARATOR
Intervention: Nonstunted comparison group (65 participants)
Number of subjects: 105
Study 22616015 — intervention group
Group type: EXPERIMENTAL
Intervention: Bananas (BAN)
Number of subjects: 14
Study 22616015 — intervention group
Group type: COMPARATOR
Intervention: 6% carbohydrate drink (CHO)
Number of subjects: 14
Study 21092774 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic endovascular aortic repair (TEVAR) with optimal medical therapy (n = 72)
Number of subjects: 140
Study 21092774 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy (n = 68)
Number of subjects: 140
Study 18365278 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant applied to gastrojejunal and jejunojejunal anastomoses and over mesenteric openings
Number of subjects: 320
Study 18365278 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fibrin sealant; suture of the mesenteric openings)
Number of subjects: 320
Study 15691531 — intervention group
Group type: EXPERIMENTAL
Intervention: TRP-deficient amino acid drink
Number of subjects: 28
Study 15691531 — intervention group
Group type: COMPARATOR
Intervention: TRP-supplemented amino acid drink
Number of subjects: 28
Study 12867220 — intervention group
Group type: EXPERIMENTAL
Intervention: IM fulvestrant 50 mg
Number of subjects: 200
Study 12867220 — intervention group
Group type: EXPERIMENTAL
Intervention: IM fulvestrant 125 mg
Number of subjects: 200
Study 12867220 — intervention group
Group type: EXPERIMENTAL
Intervention: IM fulvestrant 250 mg
Number of subjects: 200
Study 12867220 — intervention group
Group type: COMPARATOR
Intervention: Oral tamoxifen 20 mg
Number of subjects: 200
Study 12867220 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 200
Study 12906937 — intervention group
Group type: EXPERIMENTAL
Intervention: 5mg prednisolone daily
Number of subjects: 20
Study 12906937 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 20
Study 10220832 — intervention group
Group type: EXPERIMENTAL
Intervention: Gly‐X‐Y repeat sequences (active drug)
Number of subjects: 36
Study 10220832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 7838040 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A1 followed by alternating treatment with regimen B and intensified A1 (group 1)
Number of subjects: 110
Study 7838040 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A1 followed by alternating treatment with regimen C and intensified A1 (group 2)
Number of subjects: 110
Study 7838040 — intervention group
Group type: EXPERIMENTAL
Intervention: Supralethal therapy and bone marrow transplantation (BMT) (group 3)
Number of subjects: 110
Study 7838040 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow transplantation (BMT)
Number of subjects: 110
Study 2115044 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 x 100 mg testosterone pellets
Number of subjects: 43
Study 2115044 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 x 200 mg testosterone pellets
Number of subjects: 43
Study 2115044 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 200 mg testosterone pellets
Number of subjects: 43
Study 2115044 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg testosterone pellets
Number of subjects: 43
Study 2115044 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone pellets
Number of subjects: 43
Study 342729 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid therapy at a dosage of 15 mg/kg/day or more
Number of subjects: 12
Study 342729 — intervention group
Group type: COMPARATOR
Intervention: Chenodeoxycholic acid therapy at a dosage of less than 15 mg/kg/day
Number of subjects: 12
Study 342729 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid therapy
Number of subjects: 12
Study 29843840 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency Department (ED) treatment services
Number of subjects: 115
Study 27729440 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention (Group 1)
Number of subjects: 20000
Study 27729440 — intervention group
Group type: COMPARATOR
Intervention: Later intervention (Group 2)
Number of subjects: 20000
Study 25019269 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 24
Study 25019269 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C (MMC)
Number of subjects: 24
Study 23876832 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced online weight-loss program
Number of subjects: 301
Study 23876832 — intervention group
Group type: COMPARATOR
Intervention: Basic online weight-loss program
Number of subjects: 301
Study 21991731 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal pethidine
Number of subjects: 60
Study 21991731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19212327 — intervention group
Group type: COMPARATOR
Intervention: Indwelling urinary catheter placement (CG)
Number of subjects: 0
Study 19212327 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-placement of indwelling urinary catheter (UG)
Number of subjects: 0
Study 17097276 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic withdrawal
Number of subjects: 2
Study 17097276 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic stable antipsychotic treatment
Number of subjects: 2
Study 17097276 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication withdrawal
Number of subjects: 2
Study 14702509 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate
Number of subjects: 43
Study 14702509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 11704477 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 43
Study 11704477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 9212963 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally roller pumpless CPB system
Number of subjects: 30
Study 8426406 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxisylyte (10 mg)
Number of subjects: 73
Study 8426406 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxisylyte (20 mg)
Number of subjects: 73
Study 8426406 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxisylyte (30 mg)
Number of subjects: 73
Study 8426406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 3119443 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin patch system with discontinuous drug release (7.5 mg/24 hours)
Number of subjects: 10
Study 31533646 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-led HIV self-testing (HIVST)
Number of subjects: 0
Study 31533646 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 0
Study 28703448 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief support
Number of subjects: 250
Study 28703448 — intervention group
Group type: EXPERIMENTAL
Intervention: Hunger training
Number of subjects: 250
Study 28703448 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 250
Study 26095190 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 0
Study 26095190 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 0
Study 26095190 — intervention group
Group type: COMPARATOR
Intervention: Exenatide
Number of subjects: 0
Study 26095190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26095190 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 0
Study 24579284 — intervention group
Group type: EXPERIMENTAL
Intervention: PerioBalance (Lactobacilli reuteri‐CFU of 200 million) lozenges for 28 days
Number of subjects: 60